ArticleFrontiers in public health2022
Drug sensitivity of clinical isolates of
Article in Frontiers in public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 17 citations in OpenAlex.
- The Ethiopian Third National Tuberculosis Drug Resistance Survey Incorporating Whole Genome Sequencing.Open forum infectious diseases · 2025Article
- Characterization of Drug Resistance Patterns, Mutation Profiles and Prevalence ofInfection and drug resistance · 2025Article
- Genetic diversity ofNew microbes and new infections · 2024Article
- Discordance between genotypic and phenotypic methods for the detection of rifampicin and isoniazid resistantJournal of clinical tuberculosis and other mycobacterial diseases · 2024Article
- Spiritual Holy Water Sites in Ethiopia: Unrecognized High-Risk Settings for Transmission of Pulmonary Tuberculosis.International journal of microbiology · 2024Article
- Whole-genome sequencing-based genetic diversity, transmission dynamics, and drug-resistant mutations inFrontiers in public health · 2024Article
- Patterns and profiles of drug resistance-conferring mutations inFrontiers in public health · 2024Article
- Molecular typing and drug sensitivity profiles ofJournal of clinical tuberculosis and other mycobacterial diseases · 2023Article
- First and Second-Line Anti-Tuberculosis Drug-Resistance Patterns in Pulmonary Tuberculosis Patients in Zambia.Antibiotics (Basel, Switzerland) · 2023Article
- Characteristics of TB/HIV Co-Infection and Patterns of Multidrug-Resistance Tuberculosis in the Northwest Amhara, Ethiopia.Infection and drug resistance · 2023Article
- Article
- Article
- Molecular epidemiology of tuberculosis in the Somali region, eastern Ethiopia.Frontiers in medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 6 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Drug resistance is becoming a major bottleneck for tuberculosis (TB) control programs in countries with high TB burdens. Although several studies were conducted on the drug sensitivity of Methods: A total of 302 Results: The overall prevalence of resistance to at least one drug was 11.6% (95% CI: 7.9-15.2%), while the prevalence of MDR was 3.3% (95% CI: 1.3-5.3%). Two of the 10 MDR isolates were resistant to capreomycin. The spoligotype Shared International Type (SIT) 149 was significantly associated with either monoresistance or MDR ( Conclusion: The magnitude of MDR
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.